Overview of Dilora

Dilora is a synthetic pharmaceutical preparation whose core active ingredient is Desloratadine, belonging to the antihistamine class of drugs. It is classified as a modern second-generation antihistamine intended for oral use to achieve a systemic effect throughout the body.

Quick Facts: Dilora (Desloratadine)

Property	Description
Active Ingredient	Desloratadine
Form	Tablet, Oral Dissolving Tablet, Syrup (Oral Solution)
Pharmacological Class	Second-Generation Antihistamine
General Purpose	Anti-allergic agent, Histamine blocking
Origin	Synthetic, Active metabolite of Loratadine

What Type of Medicine is Dilora?

Dilora is a second-generation antihistamine, a specific classification within the pharmacological class of anti-allergy agents. The active ingredient, Desloratadine, is chemically a tricyclic antihistamine and is the principal active metabolite of the older drug Loratadine, confirming its origin as a derivative compound. Pharmacological studies confirm that Desloratadine functions as a highly selective peripheral H1-receptor antagonist. This means the medication targets the allergic response specifically outside the central nervous system, which is a key distinguishing feature that provides essential relief without the sedation associated with older classes of medicine.

Composition and Available Forms of Dilora

Dilora is a single active ingredient product containing only Desloratadine combined with a solid or liquid base/vehicle appropriate for oral delivery. The drug is supplied in various pharmaceutical preparations for oral use, including a standard solid tablet, an oral dissolving tablet, and a liquid syrup or oral solution. The availability of the liquid syrup is particularly important as it targets ease of use for pediatric patients, a formulation commonly used in children. These varied dosage forms ensure that the medication is easily adaptable to different target audiences, facilitating consistent systemic absorption of the active ingredient.

The General Purpose of Dilora

The general purpose of Dilora is to function as a highly effective anti-allergic agent. Its physiological action involves competitive histamine blocking, which means Desloratadine prevents the inflammatory chemical histamine from attaching to the H1-receptor sites on cells. By interrupting this process, the drug is clinically recognized for its ability to help manage the initial physiological effects of allergy symptoms and associated inflammation, delivering systemic relief while retaining its distinct non-sedating characteristic.

What side effects are possible with Dilora?

Possible Side Effects and Safety Information

The safety profile of Dilora (Desloratadine) is derived from controlled clinical trials and ongoing worldwide post-marketing surveillance, as documented in official regulatory sources.

Common and Infrequent Adverse Reactions

The most common adverse reactions reported in adult and adolescent patients taking the recommended daily dose in clinical trials included headache, fatigue, and dry mouth [EMA SmPC]. These general systemic effects are classified primarily under Nervous System Disorders and General Disorders.

Effects reported as very rare or from post-marketing surveillance include reactions across multiple physiological systems. These may include somnolence (drowsiness), insomnia, dizziness, nausea, and myalgia (muscle pain).

Serious Adverse Reactions and Safety Constraints

Serious reactions, typically classified as very rare or of not known frequency, have been identified through post-marketing reports and affect critical systems:

Immune System and Dermatological Reactions: Serious hypersensitivity reactions have been documented, including anaphylaxis and angioedema.
Hepatobiliary Disorders: Very rare effects impacting the liver are listed, such as hepatitis and jaundice.
Cardiac Disorders: Reports include rare events like tachycardia (rapid heart rate) and heart rhythm disorders such as QT prolongation.

Specific safety constraints are provided in regulatory documents. Caution is advised for patients with severe hepatic impairment or severe renal insufficiency due to the potential for slower drug clearance. Furthermore, the active substance should be administered with caution to patients with a personal or familial history of seizures [FDA DailyMed].

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents state that the adverse event profile associated with Dilora overdose is similar to that seen with therapeutic doses, but the magnitude of the effects can be higher. Documented manifestations, reflecting magnified known adverse events, may include fatigue, dry mouth, headache, somnolence, dizziness, tachycardia, and palpitations.

The immediate action required is to seek immediate medical attention for any suspected overdose or the onset of severe symptoms. Urgent care is necessary due to the potential for serious outcomes, including cardiac arrhythmia, QT prolongation, and seizures, which mandate close clinical observation. Cardiac monitoring may be required following large overdoses.

No specific antidote for Dilora is known or documented in the official prescribing information. Management is centered on supportive care: symptomatic and supportive treatment is recommended, and standard measures to remove unabsorbed active substance should be considered. Regulatory data also confirms that Desloratadine is not eliminated by haemodialysis.

In pediatric patients, specific post-marketing surveillance reports note an increased incidence of new-onset seizures, in addition to reports of QT prolongation, arrhythmia, and bradycardia.

Therapeutic Uses of Dilora

Dilora is commonly used across therapeutic domains to provide symptomatic support for distressing allergic manifestations. It is considered relevant in contexts where short-term symptomatic assistance is needed and supports general well-being during symptomatic phases.

The medication is primarily applied in addressing two major conditions characterized by periods of heightened symptoms: Allergic Rhinitis (both seasonal hay fever and perennial forms) and Chronic Idiopathic Urticaria (hives). It helps manage symptoms related to inflammatory or irritative states, including persistent sneezing, runny nose, nasal congestion, itchy eyes, pruritus (itching), and the presence of raised wheals.

The medication's primary benefit is that it provides supportive relief when symptoms interfere with routine activities, which may help patients cope more steadily with symptom fluctuations.

Relief for Allergic Rhinitis and Hives

This domain covers the symptoms related to physical discomfort that create noticeable physiological strain. Dilora is applied in addressing the symptom clusters of rhinitis, helping to ease the discomfort of the upper airways and eyes, while simultaneously assisting with the recurrent episodes of itching and hives characteristic of urticaria. Contributes to improved day-to-day comfort and assists with easing the overall symptom load during periods of heightened discomfort.

Quick Fact: Symptomatic Support Dilora is commonly used to help address the symptoms of both respiratory (nasal/ocular) and dermatological (skin) allergic manifestations.

Regulatory References

DailyMed (NIH) Information on Desloratadine

Eligibility and Restrictions for Use

Dilora (Desloratadine) eligibility rules are strictly defined by regulatory authorities based on age, existing health conditions, and patient status. The core rule set dictates who is explicitly contraindicated from using the medicine and under what circumstances it requires caution or restriction.

Classification	Status and Population	Official Regulatory Status
Contraindicated	Patients with known hypersensitivity to desloratadine, any excipient, or the related drug loratadine must not use Dilora.	Absolute Exclusion
Age-Eligible	Adults and Adolescents (12 years and older) are approved for use. Children use is established in specific forms (liquid) from 6 months of age for certain conditions.	Established Use
Age-Restricted	Safety and effectiveness are not established for infants younger than 6 months of age. The 5 mg tablet is typically not recommended for children under 12.	Use Not Established
Conditional Use	Patients with severe hepatic impairment or severe renal impairment must use the medication with caution. Dosage adjustment is officially recommended for adults in these populations.	Caution Required
Physiological State	Use is not recommended during lactation/breastfeeding because the drug is excreted into human milk. Use during pregnancy is generally preferable to avoid as a precautionary measure.	Restricted Status

Use in patients with a medical or family history of seizures also requires caution. The specific formulation used may be restricted for patients with conditions like Phenylketonuria (PKU) due to excipient content.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Dilora (Desloratadine) is defined by pharmacokinetic alterations (exposure) and pharmacodynamic considerations.

Documented Pharmacokinetic Interactions

Co-administration with certain medicinal products results in increased plasma concentrations (AUC and Cmax) of desloratadine and its active metabolite. These interacting medicines include the macrolide antibiotics Erythromycin and Azithromycin, the azole antifungal Ketoconazole, the H2 receptor antagonist Cimetidine, and the SSRI antidepressant Fluoxetine. While exposure is increased by these substances, regulatory studies have reported no clinically important changes in the drug's safety profile, including cardiac parameters.

Desloratadine is also recognized as a substrate for the P-glycoprotein (P-gp) efflux transporter, indicating that co-administration with P-gp inhibitors may result in altered systemic exposure.

Pharmacodynamic and Substance Interactions

Clinical pharmacology studies documented that Desloratadine did not potentiate the performance-impairing effects of alcohol or increase somnolence. However, due to post-marketing reports of alcohol intolerance and intoxication, official product information advises caution with concomitant alcohol use. There are no explicitly stated regulatory restrictions against co-administration with food; Dilora may be taken with or without a meal as food does not significantly affect the drug's absorption.

Population-Specific Interaction Notes

Due to reduced clearance, Desloratadine exposure (AUC and Cmax) is officially noted to be significantly increased in patients with hepatic impairment and renal impairment, a factor relevant for overall exposure considerations.

Mechanism of Action

H1 Receptor Blockade and Anti-Histamine Action

Dilora acts as a selective antagonist to the Histamine H1 receptor, binding to the receptor site and stabilizing its inactive conformation. This molecular interaction prevents the body's endogenous histamine from binding and activating the receptor. This initial action interrupts the chemical signaling cascade, directly attenuating the downstream signaling activated by histamine in peripheral target tissues.

Modulating Localized Inflammatory Responses

By blocking the H1 receptor, the drug prevents histamine from triggering cellular events that cause vasodilation and increased capillary permeability. This mechanism modulates key pathways within the Localized Inflammatory Mediator Signaling Cascade, thereby altering the physiological condition of capillary permeability and fluid extravasation.

Peripheral Selectivity and Neural Effects

Dilora exhibits peripheral selectivity due to its limited ability to penetrate the blood-brain barrier ( BBB) at typical concentrations. Its mechanism focuses on tissue-level targets, which limits the histamine-driven stimulation of sensory nerve endings. This results in the modulation of C-fiber afferent signaling.

Dosage and Administration Information

How to Use Dilora

Dilora (Desloratadine) is an anti-allergic medication administered exclusively via the oral route as a tablet, an oral dissolving tablet, or an oral solution (syrup). The medicine is generally taken once daily, and the labeled instructions permit administration without regard to meals (with or without food), allowing for consistent scheduling.

Standard Dosing and Frequency

The standard regimen for adults and adolescents aged 12 years and older is a 5 mg dose taken once every 24 hours. The duration of use is not fixed but depends on the type of allergic condition being managed; for instance, treatment may be intermittent (short-term) for seasonal symptoms or continuous for persistent or chronic forms of rhinitis or urticaria.

Administration for Specific Populations

Official prescribing information specifies dose adjustments for certain populations to maintain appropriate systemic exposure:

Renal or Hepatic Impairment (Adults): For patients with impaired kidney or liver function, the standard starting dose is reduced to 5 mg every other day.
Pediatric Dosing: For children, the dose is adjusted by age group and is typically given as the oral solution (0.5 mg/mL):
- 6 to 11 months: 1 mg once daily.
- 12 months to 5 years: 1.25 mg once daily.
- 6 to 11 years: 2.5 mg once daily (or the tablet form).

When using the oral solution, accurate volume measurement via a calibrated device is required. Oral dissolving tablets should be used immediately upon opening the blister pack.

Recent Clinical Evidence

Research evidence / Overview of studies for Dilora

The research base for Dilora (Desloratadine) includes human clinical studies, primarily Randomized, Double-Blind, Placebo-Controlled Trials (RCTs) and scientific reviews referenced by major regulatory bodies globally. The evidence contributes to understanding symptom patterns during the study periods.

Evidence for Use in Allergic Rhinitis (Hay Fever)

Research for allergic rhinitis involved numerous short-term RCTs, typically lasting two to four weeks. These studies were conducted to evaluate outcomes related to symptom change over time in large groups of adults and adolescents. Researchers evaluated the Total Symptom Scores (TSS), which capture the severity of key allergic manifestations, including persistent sneezing, a runny or congested nose, and itching or watering of the eyes. Research also monitored objective data points, such as changes in nasal airflow, in addition to patient-reported outcomes. Studies conducted during periods of increased symptom activity reported patterns in measured outcomes across the study duration. However, the evidence is limited to short-term findings, restricting insight into the pattern of symptoms over long periods.

Evidence for Use in Chronic Idiopathic Urticaria (Hives)

For Chronic Idiopathic Urticaria (CIU), research involved randomized, placebo-controlled clinical trials, typically lasting about six weeks. The primary outcomes measured included patient-reported Pruritus (Itching) Severity and clinician-observed measurements of the number and size of wheals. Studies also monitored outcomes reflecting daily functioning or activity level by measuring changes in patient-reported quality of life, particularly related to sleep interference. Trials reported observations where these key outcomes exhibited varying patterns between the Desloratadine group and the placebo group, with changes being observed rapidly and throughout the six-week study duration.

Evidence Gaps and Areas for Further Research

Comparative evidence is lacking when assessing Dilora against all currently available second-generation antihistamines across every possible measured outcome. Furthermore, as the pivotal efficacy trials used limited follow-up durations, the long-term effects are not fully established, and long-term maintenance outcomes are not well characterized. Additionally, the enzyme responsible for Desloratadine's metabolism has not been fully identified.

Frequently Asked Questions (FAQ)

Common questions about Dilora (FAQ)

Q: What is the main reason doctors prescribe Dilora?

Official regulatory documents state that Dilora is officially indicated for the management of symptoms associated with various allergic conditions. This includes perennial (year-round) and seasonal allergies like hay fever, known medically as Allergic Rhinitis. It is also indicated for managing the symptoms of Chronic Idiopathic Urticaria, which is a common form of persistent hives.

Q: How quickly does Dilora start working for its intended use?

Studies examining how the body handles Dilora indicate that the active ingredient, desloratadine, can be detected in the bloodstream within about 30 minutes following administration. The maximum concentrations in the body are generally reached around three hours after the dose is taken.

Q: What should I do if I miss a dose of Dilora?

Official patient information describes that a missed dose is generally taken as soon as it is remembered. However, if it is close to the time of the next scheduled dose, it is indicated that the missed dose should be skipped. Official guidelines caution against taking a double dose to compensate for a missed one.

Q: Is there a generic version of Dilora available?

Yes, Dilora is the brand name for the active ingredient desloratadine, which is available both as the original reference brand and as a generic medicine. Generic versions contain the same active ingredient and are required to meet the same regulatory standards for quality and consistency.

Q: Does Dilora cause weight gain?

Official post-marketing surveillance reports for the active ingredient, desloratadine, include reports of weight increase, which is considered uncommon. The full regulatory safety information details the frequency of this and other reported effects.

Q: Does Dilora interact with popular cold or flu medications?

The official regulatory information explicitly lists specific prescription medications that interact with Dilora, such as certain antibiotics and antifungals. While popular over-the-counter cold and flu medications are not explicitly listed, official guidance emphasizes the need to inform a healthcare professional about all medicines being taken.

Q: Can I take Dilora if I am taking over-the-counter supplements?

Regulatory documents on drug interactions primarily focus on other medicines and food, with limited information on specific interactions with over-the-counter herbal remedies or nutritional supplements. Official regulatory texts advise informing a healthcare provider or pharmacist about the use of all supplements.

Q: What is the official classification of Dilora (e.g., controlled substance)?

Dilora's regulatory status in many regions classifies it as a Prescription-Only Medicine (POM), meaning it requires a prescription from a licensed professional. Official records from the US Drug Enforcement Administration indicate that it is not listed as a controlled substance.

Q: Where can I find the official patient information leaflet for Dilora?

Official patient information can be found on government-run websites like the NIH DailyMed and MedlinePlus in the United States. Furthermore, the complete Patient Information Leaflet (PIL) for the product is often available on the websites of the national regulatory authority in your country.

Q: What is the difference between Dilora and [Name of similar common drug]?

Dilora's mechanism classifies it as a selective peripheral H1-receptor antagonist. This means its action is focused outside the central nervous system, classifying it as a non-sedating and long-acting medicine. This specific pharmacological classification provides the basis for how regulatory documents distinguish it from other antihistamines.

Q: Does Dilora have a warning about driving or operating machinery?

Based on clinical trial data reviewed by regulatory bodies, Dilora is indicated to have no or negligible influence on a person's ability to drive or use machines, as it generally does not cause drowsiness. However, official product information suggests that individuals should establish their personal response to the medicine before engaging in tasks that require complete mental alertness.

Q: How does Dilora affect blood pressure?

The active ingredient in Dilora is not commonly reported to have a direct effect on blood pressure. However, regulatory post-marketing data includes rare reports of cardiac events like tachycardia (rapid heart rate). If Dilora is used in combination with other decongestant drugs, that combination may potentially affect blood pressure.

Q: Are there any vitamins or minerals that Dilora interacts with?

Official drug interaction data typically lists other medications, specific foods, and substances like alcohol. Specific interactions with individual vitamins or minerals are not widely detailed in the regulatory texts. Official guidance advises informing a healthcare provider about all supplements being used.

Q: Can Dilora be crushed or split?

Official instructions provide details for administering the oral solution and the oral dissolving tablet (ODT) forms. However, regulatory documents do not provide instruction or guidance on splitting or crushing the standard film-coated tablet form. This indicates that regulatory documentation is based on the standard tablet being swallowed whole.

Q: How is Dilora removed from the body?

The process by which the body clears the active ingredient, desloratadine, involves elimination through both the urine and feces. Official pharmacokinetic data indicates the drug has a long terminal half-life, which is the time it takes for the concentration to reduce by half, of approximately 27 hours.

Q: What is the purpose of the inactive ingredients in Dilora?

The ingredients in Dilora that are not the active medicine are known as excipients or inactive ingredients. For tablets, their purpose is to function as binders, fillers, and lubricants to ensure the pill is properly formed and dissolves correctly for absorption. For the liquid solution, they act as the vehicle, flavoring, and preservative.

Q: Does Dilora have a boxed warning?

The US Food and Drug Administration (FDA) uses a specific communication known as a Boxed Warning, or Black Box Warning, to highlight certain serious safety concerns. The official Prescribing Information for Dilora (Desloratadine) does not currently include this specific type of warning.

Q: Is Dilora a new medication or has it been around for a while?

Dilora, with the active ingredient desloratadine, is not considered a new medication. It was first approved by the US FDA in December 2001, meaning it has been available for use for over two decades. It is classified as a modern second-generation antihistamine.

Q: Why is Dilora only available by prescription?

In many regions, Dilora has the regulatory classification of a Prescription-Only Medicine (POM). This status is assigned because the medicine requires professional oversight to ensure that it is used correctly and that rare potential side effects, such as those related to the heart, can be monitored by a healthcare professional.

How should Dilora be stored and disposed of?

The official storage and disposal requirements for Dilora (Desloratadine) are defined by regulatory agencies to maintain product stability and ensure public safety.

Scope Item	Official Regulatory Requirement
Storage Temperature	Store at controlled room temperature, generally between 20°C and 25°C (68°F and 77°F).
Protection	Keep the medicine away from excess heat, light, and moisture; storage must be in the original container, tightly closed [Source 2.4].
Handling Rule	The product must be kept from freezing [Source 2.7]. For oral dissolving tablets, do not remove the dose from the blister until immediate use.
Child Safety	Mandatory to store the medication out of the sight and reach of children [Source 2.7].
Disposal	Do not throw away medicines via wastewater or household waste [Source 3.4]. Unused or expired product should be returned to a take-back program or disposed of by mixing with an unappealing substance, as advised by a pharmacist [Source 3.5].

Regulatory documents strictly mandate these conditions to define how the product must be protected, handled, and discarded, thereby controlling environmental risks and preventing accidental exposure.

Dilora